Alnylam Pharmaceuticals Related Correlations
| ALNY Stock | USD 145.32 1.40 0.95% |
Is Alnylam Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alnylam Pharmaceuticals. If investors know Alnylam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alnylam Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Alnylam Pharmaceuticals is measured differently than its book value, which is the value of Alnylam that is recorded on the company's balance sheet. Investors also form their own opinion of Alnylam Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Alnylam Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alnylam Pharmaceuticals' market value can be influenced by many factors that don't directly affect Alnylam Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alnylam Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alnylam Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alnylam Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Correlations
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Alnylam Stock performing well and Alnylam Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Alnylam Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| PRQR | 2.97 | (0.17) | 0.00 | (0.06) | 0.00 | 6.84 | 20.48 | |||
| WVE | 3.83 | 0.01 | 0.03 | 0.05 | 4.61 | 7.82 | 44.08 | |||
| BPMC | 2.42 | 0.10 | 0.05 | 0.09 | 3.06 | 4.99 | 19.44 | |||
| APLS | 2.24 | (0.47) | 0.00 | (0.35) | 0.00 | 3.12 | 16.59 | |||
| INCY | 1.03 | (0.25) | 0.00 | (0.61) | 0.00 | 1.87 | 6.54 | |||
| UTHR | 1.14 | 0.11 | 0.04 | 1.06 | 1.39 | 2.67 | 9.90 | |||
| RARE | 2.14 | (0.02) | 0.01 | 0.04 | 2.73 | 4.25 | 15.57 | |||
| BMRN | 0.95 | (0.06) | 0.00 | (0.08) | 0.00 | 1.94 | 5.18 | |||
| SGEN | 0.51 | 0.14 | 0.21 | (6.39) | 0.17 | 1.20 | 5.21 | |||
| EXEL | 1.03 | (0.01) | (0.02) | 0.03 | 1.75 | 1.67 | 9.57 |